Shares of Quidel Corporation (QDEL) soared 8.70% in pre-market trading on Thursday, following a significant target price upgrade from UBS. The Swiss investment bank raised its price target for QuidelOrtho from $26 to $31, signaling increased confidence in the company's future performance.
The substantial target price increase of 19.2% from UBS has sparked investor interest in the healthcare diagnostics company. This positive outlook from a major financial institution suggests that QuidelOrtho's business prospects and growth potential may be stronger than previously anticipated.
Additionally, analysts have been showing mixed opinions on various healthcare stocks, including QuidelOrtho, as reported in recent market analyses. This heightened attention from the financial community could be contributing to the increased trading activity and positive sentiment surrounding QDEL stock.
Comments